Roivant Sciences (NASDAQ:ROIV) Shares Gap Up to $3.70

Roivant Sciences Ltd. (NASDAQ:ROIVGet Rating)’s share price gapped up before the market opened on Monday . The stock had previously closed at $3.70, but opened at $3.96. Roivant Sciences shares last traded at $3.90, with a volume of 2,577 shares.

Several equities analysts recently commented on ROIV shares. Zacks Investment Research lowered Roivant Sciences from a “hold” rating to a “sell” rating in a research report on Friday, February 18th. SVB Leerink assumed coverage on Roivant Sciences in a report on Monday. They set an “outperform” rating and a $6.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on Roivant Sciences in a report on Friday, April 29th. They set an “overweight” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.29.

The stock has a fifty day moving average price of $4.19 and a two-hundred day moving average price of $6.57.

In related news, COO Eric Venker sold 80,045 shares of the company’s stock in a transaction on Friday, March 25th. The stock was sold at an average price of $5.06, for a total transaction of $405,027.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Matthew Gline sold 92,324 shares of the company’s stock in a transaction on Monday, March 7th. The stock was sold at an average price of $5.52, for a total value of $509,628.48. The disclosure for this sale can be found here. Insiders sold a total of 372,113 shares of company stock valued at $1,902,993 over the last quarter.

A number of hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC boosted its position in Roivant Sciences by 25.4% during the 1st quarter. Hsbc Holdings PLC now owns 14,684 shares of the company’s stock worth $71,000 after acquiring an additional 2,978 shares during the period. Bank of New York Mellon Corp boosted its position in Roivant Sciences by 10.1% during the 1st quarter. Bank of New York Mellon Corp now owns 47,274 shares of the company’s stock worth $233,000 after acquiring an additional 4,335 shares during the period. Citigroup Inc. boosted its position in Roivant Sciences by 1,803.6% during the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock worth $28,000 after acquiring an additional 5,447 shares during the period. Royal Bank of Canada boosted its position in Roivant Sciences by 60,550.0% during the 1st quarter. Royal Bank of Canada now owns 6,065 shares of the company’s stock worth $30,000 after acquiring an additional 6,055 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in Roivant Sciences during the 4th quarter worth $108,000. Institutional investors own 61.49% of the company’s stock.

About Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.

Recommended Stories

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.